【辉瑞】辉瑞Braftovi二药方案获批用于BRAF V600突变的mCRC患者( 二 )


2、BEACON CRC: A Randomized, 3-Arm, Phase 3 Study of Encorafenib and Cetuximab With or Without Binimetinib vs. Choice of Either Irinotecan or FOLFIRI, plus Cetuximab in BRAFV600E Mutant Metastatic Colorectal Cancer. Retrieved December 18, 2019, from


推荐阅读